scholarly journals Secretory breast carcinoma in a female adult with liver metastsis: a case report and literature review

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Jing Lian ◽  
Li-Xia Wang ◽  
Jiang-hong Guo ◽  
Peng Bu ◽  
Yan-feng Xi ◽  
...  
Keyword(s):  
Liver Metastasis ◽  
Breast Carcinoma ◽  
Poor Prognosis ◽  
Hormone Receptors ◽  
Fatal Outcome ◽  
Radical Mastectomy ◽  
Distant Metastases ◽  
Left Breast ◽  
Secretory Breast Carcinoma

Abstract Background Secretory breast carcinoma is an uncommon subset of breast cancer that usually has a favorable outcome. Although initially described in children, it also occurs in adults where it may metastasize, possibly resulting in death. To date, only 20 cases of secretory breast carcinoma with distant metastases have been described. Case presentation A 42-year-old female presented with liver metastasis after modified radical mastectomy of the left breast in 2008 at 34 years of age. The liver metastasis was morphologically similar to the primary tumor. Pan-TRK and Fluorescence in situ hybridization showed a rearrangement in the ETV6 gene. She subsequently underwent adjuvant chemotherapy with a fatal outcome. Conclusions Although secretory breast carcinoma is usually associated with favorable outcomes, our study and reviews provide a novel insight into the genetic spectrum and treatment of secretory breast carcinoma showing reduced expression of hormone receptors, abnormal genomic profiles, and possible poor prognosis. Targeted therapy may curb clinically aggressive cases. Additional molecular investigations are needed to determine the links between specific mutations and poor prognosis.

scholarly journals Y-Box binding protein 1 expression in breast cancer and its correlation with hormone receptors and other prognostic markers

2018 ◽  
Vol 10 (04) ◽  
pp. 420-425 ◽  
Author(s):  
Taruna Bansal ◽  
Nadeem Tanveer ◽  
Usha Rani Singh ◽  
Sonal Sharma ◽  
Navneet Kaur
Keyword(s):  
Breast Carcinoma ◽  
Hormone Receptors ◽  
Prognostic Markers ◽  
Binding Protein ◽  
Radical Mastectomy ◽  
Positive Association ◽  
Tumor Stage ◽  
Lymph Node Involvement ◽  
Clinical Parameters ◽  
Node Involvement

Abstract INTRODUCTION: The present histologic and immunohistochemical prognostic markers of breast carcinoma do not effectively identify the subset of patients with poor prognosis. Y-Box binding protein 1 (YB1) is a novel biomarker which may identify and aid in targeted personalized therapy for such patients. MATERIALS AND METHODS: The study was conducted on histopathology specimens of 74 patients of breast carcinoma who had undergone modified radical mastectomy. YB1 immunohistochemistry (IHC) was performed on manual tissue microarray blocks (each having 15 cores). The YB1 expression was quantified in terms of “immunoreactive score” which was correlated with clinical parameters, hormone receptor status, and Her2neu overexpression by IHC. The Her2neu status of the equivocal cases was further evaluated by fluorescent in situ hybridization (FISH). RESULTS: YB1 was positive in 36/74 (48.6%) cases. On IHC and analysis by FISH, 25/74 (34%) cases had Her2neu overexpression. Estrogen receptor (ER) and progesterone receptor (PR) positivity was found in 42% and 36.5% cases, respectively. YB1 immunopositivity was negatively correlated with ER and PR expression, but showed a significant positive correlation with Her2neu expression. No correlation was found with other clinical parameters, tumor stage, and grade, except lymph node involvement, which showed a positive association with YB1 expression. Triple-negative breast carcinoma constituted 25.6% of the total cases, out of which 73.6% were YB1 positive. CONCLUSION: This study found that YB1 has an association with Her2neu expression. It may in future provide a therapeutic target in Her2neu overexpressing tumors.

Aggressive malignant phyllodes tumor of breast with omental metastases – A case report

2021 ◽  
Vol 40 (4) ◽  
pp. 287-291
Author(s):  
B. Rajkrishna ◽  
Rajesh Balakrishnan ◽  
Mithun Raam ◽  
A. Santhosh Raj ◽  
Patricia Sebastian ◽  
...  
Keyword(s):  
Radical Mastectomy ◽  
Phyllodes Tumor ◽  
Distant Metastases ◽  
Left Breast ◽  
Adjuvant Radiation ◽  
Left Chest ◽  
Dismal Prognosis ◽  
Phyllodes Tumour ◽  
Flap Cover ◽  
Malignant Phyllodes Tumour

Distant metastasis from malignant Phyllodes tumour (PT) is rare. They generally metastasize to the lung, bone, pleura, and liver. We present a very rare case of a 25-year-old woman with intraabdominal metastases from malignant phyllodes tumour of the breast. She presented with left breast lump and the biopsy was Phyllodes tumour. She underwent a two staged surgery; left modified radical mastectomy followed by left latissimus dorsi musculocutaneous flap cover. She received adjuvant radiation therapy to left chest wall. Following which she developed intrabdominal mass which was proven to be metastasis from Phyllodes tumour. She was then advised palliative chemotherapy. Malignant Phyllodes with distant metastases has a dismal prognosis. We propose it is preferable to have a CT Thorax and Abdomen as a staging workup for patients with malignant PT to identify those with poor prognosis.

A fluorescence in situ hybridization study ofETV6-NTRK3 fusion gene in secretory breast carcinoma

2004 ◽  
Vol 40 (2) ◽  
pp. 152-157 ◽  
Author(s):  
Nikita Makretsov ◽  
May He ◽  
Malcolm Hayes ◽  
Stephen Chia ◽  
Doug E. Horsman ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Breast Carcinoma ◽  
Fluorescence In Situ Hybridization ◽  
Fusion Gene ◽  
Hybridization Study ◽  
Secretory Breast Carcinoma

scholarly journals Chromogenic in Situ Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma

2019 ◽  
Vol 7 (12) ◽  
pp. 1917-1925
Author(s):  
Ali Hussein Mohammed Ali ◽  
Alaa Qasim Yahya ◽  
Haider Latteef Mohammed
Keyword(s):  
In Situ Hybridization ◽  
Breast Carcinoma ◽  
Gene Amplification ◽  
Hormone Receptors ◽  
In Situ Hybridisation ◽  
Invasive Breast Carcinoma ◽  
Tier System ◽  
Chromogenic In Situ Hybridization ◽  
Gene Status

BACKGROUND: The rapidly growing knowledge regarding factors controlling tumour growth, with the new modalities of therapy acting on the biological activity of the tumours draw the attention of most cancer researches nowadays and represent a major focus for clinical oncology practice. For the detection of HER2/neu protein overexpression and gene amplification, immunohistochemistry (IHC) and in-situ hybridisation (ISH) is the recommended techniques, respectively, with high concordance between the two techniques. The current United Kingdom recommendations for HER2/neu testing are either for a two-tier system using IHC with reflex ISH testing in equivocal positive cases, or a one-tier ISH strategy. AIM: To compare the results of HER2/neu gene status in patients with breast carcinoma obtained by chromogenic in situ hybridisation with those obtained by immunohistochemistry, and to compare these results with hormonal receptors expression by immunohistochemistry and with age of patients.METHODS: Immunohistochemistry technique was used for evaluation of status of estrogen receptors (ER) and progesterone receptors (PR) and HER2/neu protein expression in 448 Iraqi patients with invasive breast carcinoma with different grades and histological types and then chromogenic in situ hybridization (CISH) technique was applied for all scores of HER2/neu to detect the gene status and compare the results in all negative, equivocal and positive cases by immunohistochemistry (IHC). The cases were referred from different centres, and IHC and CISH techniques were done in central public health laboratory in Baghdad over 28 months, from July 2013 to November 2015. A comparison of the results was made to find the relationship between HER2/neu and hormone receptors status and other clinical parameters like patients age. RESULTS: The mean age of the study cases was 49.08 years, ranging from 24 to 83 years. Of the 448 cases of breast carcinoma, 44 (9.8%) cases were of score 0 by IHC, none of them (0%) showed HER2/neu gene amplification by CISH. 71(15.8%) cases were of score 1 by IHC, 15 (21.12%) of them showed HER2/neu gene amplification by CISH, all were of low amplification. There were 306 (68.3%) cases of score 2 by IHC, of which 102 (33.33%) cases showed HER2/neu gene amplification by CISH, with 79 (25.81%) of them with low amplification and 23 (7.51%) cases with high amplification, while only one case (0.32%) remained in equivocal category. In score 3, all the 27 (6.0%) cases showed gene amplification with 12 (44.44%) cases with low amplification and 15 (55.55) cases with high amplification with overall percentage of gene amplification in score 3 of 100%. There was a significant inverse relationship between hormone receptors (ER and PR) status and HER2/neu gene amplification. No significant relationship was found between the patient’s age and HER2/neu gene amplification.CONCLUSION: Although immunohistochemistry is a widely used, less expensive and reliable test, we strongly advice performance of chromogenic in situ hybridization in assessment of HER2/neu gene status in all cases diagnosed with breast carcinoma as significant number of cases that were reported as negative by immunohistochemistry showed positive amplification by chromogenic in situ hybridization and can get benefit from anti-HER2 targeted treatments.

Different Expression of HER2/neu Oncogene in Breast Carcinoma and in Liver Metastasis. Description of a Case

2006 ◽  
Vol 92 (6) ◽  
pp. 536-539 ◽  
Author(s):  
Elisa Rossi ◽  
Edda Simoncini ◽  
Francesca Valcamonico ◽  
Giovanni Marini ◽  
Piergiovanni Grigolato ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Breast Carcinoma ◽  
Primary Tumor ◽  
Left Breast ◽  
Metastatic Carcinoma ◽  
Adequate Treatment ◽  
Her 2 ◽  
Neu Oncogene ◽  
Liver Ultrasonography

We report the clinical, morphological and molecular findings regarding a 37-year-old woman with breast cancer metastatic to the liver and describe the different expression of a tumor marker in the primary and secondary lesions and the singular responsiveness to treatment. The patient suffered from a carcinoma of the left breast with metastasis to the liver. High HER-2 protein expression assessed by immunohistochemistry and HER-2/neu amplification determined by FISH were present in the primary tumor, while the liver metastasis showed a lower value of HER-2 protein (2+) and absence of HER-2/neu amplification. The patient was treated with chemotherapy (epirubicin and paclitaxel) followed by trastuzumab and docetaxel. After 5 months, at the completion of chemo-immunotherapy, liver ultrasonography showed a further hepatic response. A second biopsy was performed on the residual liver nodule: immunohistochemistry revealed negative (1+) HER-2 expression and FISH confirmed that the HER-2/neu gene was not amplified. The different amplification of HER-2 and expression of its protein in primary and metastatic carcinoma could be important for planning adequate treatment.

scholarly journals Estrogen Receptor Positive Secretory Breast Carcinoma in a Bangladeshi Elderly Woman Diagnosed by Core Needle Biopsy

2021 ◽  
Vol 28 (2) ◽  
pp. 216-233
Author(s):  
Nafisa Abedin ◽  
Kazi Nabila Bushrah ◽  
Muhit Reza Md Muktadir ◽  
Bishnu Pada Dey
Keyword(s):  
Estrogen Receptor ◽  
Breast Carcinoma ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Left Breast ◽  
Low Grade ◽  
Core Needle ◽  
Post Menopausal ◽  
Secretory Breast Carcinoma

Secretory carcinoma is an extremely rare subtype of low grade invasive breast carcinoma and occurs infrequently in adults showing belligerent clinical course than in children. Surprisingly, it is the only epithelial carcinoma of breast representing characteristic balanced translocation.This paper reports a case of secretory breast carcinoma in an elderly post-menopausal woman in Bangladesh which is diagnosed by core needle biopsy. The majority of the case reports claimed this tumor to be a triple negative breast carcinoma, whereas our case report reveals a slightly different status in immunohistochemical context. A 78-years old, post-menopausal female presented with the chief complaints of painless, slowly enlarging lump in her left breast over nine months. Breast examination revealed a 2x1.5cm, well-delineated, firm, non-tender and mobile mass in the lower-outer quadrant of the left breast. Microscopically, the tumor was composed of cells containing PAS positive, diastase resistant and mucicarmine positive intra and extra-cellular secretory material and Alcian blue positive secretion was found extracellularly. The tumor cells showed strongly positive immunohistochemical reactivity for cytokeratin, EMA, E-cadherin and vimentin and focal positive reaction for S-100 protein and estrogen receptor but negative for both progesterone receptor and human epidermal growth factor receptor. Ki-67 proliferative index was about 4%. Hence, the diagnosis of secretory breast carcinoma (SBC) was made. The patient underwent modified radical mastectomy with axillary clearance without any axillary lymphnode involvement in an external center. The patient has not received any radio or chemotherapy. The patient was under continuous follow-up for 3-months.Unfortunately, owing to the nation-wide lockdown for dreadful COVID-19 pandemic, the patient couldn’t arrive at the hospital for further follow-up evaluation. Immunohistochemical (IHC) analysis has been proven to be an alternative potential method as gene analysis. Immunoprofiling of secretory breast carcinomas may play the pivotal role for selecting therapeutic strategies and predicting prognostic outcome of the disease process. Comprehending the immunohistochemical expression would make scope for applying targeted therapy in SBC patients in future. J Dhaka Medical College, Vol. 28, No.2, October, 2019, Page 216-223

Thirty Year Old Female Presented with Nipple Destruction: A Case Report

2019 ◽  
Vol 11 (1) ◽  
pp. 81-83
Author(s):  
Md Mustafizur Rahman ◽  
Nadim Ahmed ◽  
Sami Ahmad ◽  
Shoaeb Imtiaz Alam ◽  
Mohammad Rashedul Hassan ◽  
...  
Keyword(s):  
Invasive Carcinoma ◽  
Paget’S Disease ◽  
Radical Mastectomy ◽  
Paget's Disease ◽  
College Hospital ◽  
Rare Type ◽  
Medical College ◽  
Ductal Cell ◽  
Areola Complex

Paget’s disease of the breast is a rare type of cancer of the nipple–areola complex and that is often associated with an underlying in situ or invasive carcinoma. It is often misdiagnosed as eczema of breast and treatment is delayed. Here we present a case where a 30 year old female presented with itching ulceration and destruction of her left nipple. She was treated initially by local physicians by applying local ointments but as her condition did not improve she was admitted to department of surgery Shaheed Suhrawardy Medical College hospital where she was diagnosed as Paget’s disease with infiltrating ductal cell carcinoma. She underwent modified radical mastectomy with axillary clearance and referred to oncology department for further management. J Shaheed Suhrawardy Med Coll, June 2019, Vol.11(1); 81-83

Sign in / Sign up

Export Citation Format

Share Document